An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Besponsa

Chemical Nameinotuzumab ozogamicin
Dosage FormInjectable (intravenous; 0.9 mg/vial)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyWyeth Pharmaceuticals
Approval Year2017

Indication

  • Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Last updated on 6/9/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Besponsa (inotuzumab ozogamicin) prescribing information.2018Pfizer
Document TitleYearSource
Pan-Canadian Oncology Drug Review. Final economic guidance report. inotuzumab ozagamycin (besponsa) for acute lymphoblastic leukemia.2018CADTH
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia.2018NICE
Document TitleYearSource
NCCN guidelines version 1.2021. Acute lymphoblastic leukemia.2020NCCN evidence blocks